<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13971">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02925026</url>
  </required_header>
  <id_info>
    <org_study_id>Lactoferrin-Lysozyme</org_study_id>
    <nct_id>NCT02925026</nct_id>
  </id_info>
  <brief_title>Lactoferrin and Lysozyme Supplementation for Environmental Enteric Dysfunction</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Malawi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-blind, placebo controlled trial of daily lactoferrin and lysozyme
      supplementation in improving environmental enteric dysfunction in Malawian children
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dual Sugar Absorption Test</measure>
    <time_frame>8 weeks</time_frame>
    <description>lactulose-mannitol ratio in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dual Sugar Absorption Test</measure>
    <time_frame>16 weeks</time_frame>
    <description>lactulose-mannitol ratio in urine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lactulose Excretion</measure>
    <time_frame>8 weeks</time_frame>
    <description>percentage of ingested lactulose excreted in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactulose Excretion</measure>
    <time_frame>16 weeks</time_frame>
    <description>percentage of ingested lactulose excreted in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mannitol Excretion</measure>
    <time_frame>8 weeks</time_frame>
    <description>percentage of ingested mannitol excreted in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mannitol Excretion</measure>
    <time_frame>16 weeks</time_frame>
    <description>percentage of ingested mannitol excreted in urine</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Linear Growth</measure>
    <time_frame>16 weeks</time_frame>
    <description>changes in linear growth</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Environmental Enteric Dysfunction</condition>
  <arm_group>
    <arm_group_label>Lactoferrin+Lysozyme</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lactoferrin and lysozyme in rice flour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>rice flour</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactoferrin</intervention_name>
    <arm_group_label>Lactoferrin+Lysozyme</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lysozyme</intervention_name>
    <arm_group_label>Lactoferrin+Lysozyme</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  children aged 12-35 months

          -  youngest eligible child in each household

        Exclusion Criteria:

          -  severe or moderate acute malnutrition

          -  severe chronic illness

          -  children unable to drink 20 mL of dual sugar solution

          -  children in need of acute medical treatment for illness or injury at time of
             enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>35 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark J Manary, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University in St. Louis; University of Malawi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chrissie Thakwalakwa, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Study Director</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Indi Trehan, MD MPH DTM&amp;H</last_name>
    <role>Study Director</role>
    <affiliation>Washington University in St. Louis; University of Malawi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Indi Trehan, MD MPH DTM&amp;H</last_name>
    <phone>+1-314-881-8123</phone>
    <email>indi@alum.berkeley.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mmwenye Rural Site</name>
      <address>
        <city>Mmwenye</city>
        <state>Machinga District</state>
        <country>Malawi</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Cheng, BS</last_name>
      <phone>+265-991-458-803</phone>
      <email>williamcheng@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Indi Trehan, MD MPH DTM&amp;H</last_name>
      <phone>+1-314-881-8123</phone>
      <email>itrehan@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mark J Manary, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chrissie Thakwalakwa, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Indi Trehan, MD MPH DTM&amp;H</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malawi</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 10, 2017</lastchanged_date>
  <firstreceived_date>October 4, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muramidase</mesh_term>
    <mesh_term>Lactoferrin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
